Friday, August 14, 2026 Evidence-led medical research news
The First Cohort
Medical research, with the receipts

drug-safety

4 stories tagged "drug-safety"

Drugs & FDA

For Years the Muscle Aches Were Called a Nocebo Effect. A McMaster Lab Found Statins Injuring the Muscle Cell Itself.

An estimated 7 to 29 percent of statin users report muscle pain. The flagship trial called most of it a placebo response. In mouse and human muscle cells, a McMaster team has now traced a cholesterol-independent pathway by which statins damage muscle directly.

Drugs & FDA

The FDA Approved Narcolepsy's First Orexin Agonist. Takeda's Last One Was Pulled for Liver Injury.

Takeda's oveporexton switches on the orexin receptor that narcolepsy type 1 patients can no longer signal. The company's last orexin drug was halted in 2021 after patients crossed serious liver-injury thresholds.

Drugs & FDA

The FDA Office That Vets Gene Therapy Has Run Through Its Entire Top Tier in a Year

The office that decides whether gene therapies reach patients has lost its director, her deputy, and the man brought in to replace them, all inside twelve months.

Metabolic & Weight

Retatrutide's Triple-Receptor Triumph Came With a One-in-Five Skin-Sensation Signal Nobody Wanted to Linger On

Eli Lilly's investigational retatrutide hit bariatric-surgery-level weight loss at ADA 2026. The highest-dose arm of TRIUMPH-4 also saw 20.9% of patients report abnormal skin sensations, and a small cardiac imbalance turned up in the type-2 trial. Both got far less stage time than the headline numbe